District Court, S.D. New York August 8, 2006, No. 05 MD 1661(HB)(JCF) (In re Rivastigmine Patent Litigation)

MEMORANDUM AND ORDER

FRANCIS, United States Magistrate Judge.

This multidistrict litigation concerns the patent rights for rivastigmine tartrate (“ri*72vastigmine”), the active ingredient in Exelon, a medication marketed by Novartis Pharmaceutical Corporation (“NPC”) for the treatment of mild to moderate dementia of the Alzheimer’s type.